Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03669315
Other study ID # TMS-GD
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 20, 2018
Est. completion date December 1, 2019

Study information

Verified date September 2018
Source CNS Onlus
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this project the investigators propose a randomized double-blind placebo-controlled design in which 40 patients with GD will receive active or sham cTBS to the pre-SMA for 2 weeks. The investigators will combine TMS, multimodal structural and functional MRI and behavioral measures in order to identify circuit-level mechanisms of action and therapeutic targets (connectivity changes that explain clinical improvement) and assess the efficacy of TMS in modulating inhibitory control and symptom severity in this population.


Description:

SPECIFIC AIMS The appropriate interplay of cognitive and reward systems is essential for adaptive human behavior, allowing a homeostatic balance between immediate basic pleasures and long-term planned rewards. Deficits in inhibitory control from cortical cognitive systems over subcortical reward circuits is a key pathophysiological feature of addictive behavior that has not been studied satisfactorily in gambling disorder (GD). The clinical phenotype of this population is characterized by unsuccessful efforts to reduce or stop gambling despite negative outcomes, suggestive of faulty inhibitory control of gambling impulses that sustain the chronicity and comorbidities of this clinical syndrome. Deficits in behavioral and cognitive control constitute a symptom dimension associated with diminished response inhibition in experimental tasks such as the Stop Signal Task (SST). The pre-supplementary motor area (pre-SMA) is a key node of the cognitive control network responsible for response inhibition. Pre-SMA activation has been associated to response inhibition performance in fMRI studies using the SST and recent evidence also suggests that its activity represents a motivational signal for movement. In fact, pre-SMA seems to have a dominant role in bridging the delay between expected reward and specific actions rather than determining whether an action is made. Although the pathophysiology of GD is not well understood, studies have shown altered brain activity in prefrontal regions (including pre-SMA) of GD patients during response inhibition tasks in addition to functional connectivity abnormalities of SMA during rest. These circuit-level abnormalities represent a potential therapeutic target that could be modulated by brain stimulation therapies such as transcranial magnetic stimulation (TMS). Theta burst stimulation (TBS), is a particularly brief and effective form of TMS that can be inhibitory (continuous or cTBS) or excitatory (intermittent or iTBS). Although pre-SMA has been successfully targeted with traditional TMS and TBS for impulse-control disorders like OCD, this approach has never been tested for GD in therapeutic or mechanistic studies. Despite the significant morbidity and mortality of GD, there is a dramatic shortage of effective treatment options for these patients, partly due to the lack of valid pathophysiological models for target discovery and experimental therapeutics. In this project the investigators propose a randomized double-blind placebo-controlled design in which 40 patients with GD will receive active or sham cTBS to the pre-SMA for 2 weeks. The investigators will combine TMS, multimodal structural and functional MRI and behavioral measures in order to identify circuit-level mechanisms of action and therapeutic targets (connectivity changes that explain clinical improvement) and assess the efficacy of TMS in modulating inhibitory control and symptom severity in this population.

Aim 1 (ACUTE MECHANISM OF ACTION): To assess circuit-level effects of a single session of cTBS to the pre-SMA in GD patients. Hypothesis 1.1: cTBS will lead to increase in functional connectivity between cortical inhibitory nodes (pre-SMA) and reward subcortical structures (Nucleus Accumbens, NAc), and these changes will correlate with improvement in reaction time in SST. Hypothesis 1.2: cTBS will not lead to acute changes in FA, RD or AD in the mesocorticolimbic pathway. Hypothesis 1.3: cTBS will lead to increased cognitive control network and decreased NAc activation during SST. Exploratory analyses will test the predictive value of acute circuit changes for clinical improvement after 2 weeks and 1 month follow up.

Aim 2 (CHRONIC MECHANISM OF ACTION): To assess circuit-level effects of 10 session of cTBS to the pre-SMA in GD patients Hypothesis 2.1: cTBS will lead to increases in functional connectivity between preSMA and NAc, and these will correlate with behavioral and clinical improvement. Hypothesis 2.2: cTBS will lead to increased FA and decreased RD and AD in the mesocorticolimbic pathway, and these will correlate with clinical improvement. Hypothesis 2.3: cTBS will lead to further increased cognitive control network and decreased NAc activation during SST, and these will correlate with clinical improvement.

Aim 3 (BEHAVIORAL/CLINICAL): To determine the behavioral and clinical changes of cTBS to the preSMA in GD. Hypothesis 3.1: A single session of cTBS will lead to improvement in reaction time in the SST, but not in symptom severity measured with clinical scales. Hypothesis 3.2: 10 sessions of cTBS will lead to improvement in reaction time in the behavioral inhibition task, in addition to a reduction in clinical severity (including craving/urges) as measured by clinical scales.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 1, 2019
Est. primary completion date December 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. DSM-5 diagnosis of Gambling Disorder

2. Age between 18 and 65 years

Exclusion Criteria:

1. any additional current psychiatric comorbidity, except for nicotine addiction;

2. a lifetime DSM-5 diagnosis of schizophrenia or other psychotic syndromes, substance dependence or substance abuse, including alcohol, bipolar I or II disorder, mental disorder due to a general medical condition;

3. serious suicide risk;

4. illness duration less than two years;

5. hospitalization in the last 6 months;

6. the inability to receive TMS because of metallic implants, or history of seizures (personal or family history of seizure in first degree relatives);

7. any major medical disease;

8. pregnancy or nursing of an infant;

9. the inability or refusal to provide written informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Transcranial Magnetic stimulation
Neuromodulation tool

Locations

Country Name City State
Italy CNSOnlus, Institute of Neuroscience Florence

Sponsors (1)

Lead Sponsor Collaborator
CNS Onlus

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary cTBS effects on gambling symptoms change cTBS effects on gabling symptoms severity assessed through the PG-Y-BOCS (Yale-Brown Obsessive-Compulsive Scale modified for Pathological Gambling). Range from: 0-40 (higher values=worse symptoms) Baseline - Day 10 (after 10 cTBS sessions) - after 1 month follow-up
Primary cTBS effects on gambling symptoms change cTBS effects on gabling symptoms severity assessed through the GUQ (Gambling Urges Questionnaire). Range from: 0-60 (higher values=worse symptoms) Baseline - Day 10 (after 10 cTBS sessions) - after 1 month follow-up
Secondary Acute mechanism of action Functional MRI assessment Day 1
Secondary Chronic mechanism of action Functional MRI assessment Day 10
See also
  Status Clinical Trial Phase
Recruiting NCT03614884 - Effectiveness of an Online Integrated Treatment for Problem Gambling and Tobacco Smoking N/A
Completed NCT03946098 - ICBTG in Routine Care N/A
Completed NCT03725735 - Emotion Regulation Group Treatment for Gambling Disorder - a Pilot Trial N/A
Not yet recruiting NCT05331612 - Blended Treatment for Problem Gambling and Gambling Disorder Combining Group Sessions and Online Modules N/A
Completed NCT03145792 - Online Coping Skills Counseling for Problem Gambling and Trauma N/A
Not yet recruiting NCT03280966 - Effects of Intranasal Naloxone on Gambling Urges in Gambling Disorder Phase 2
Recruiting NCT02953899 - Contingency Management as an Adjunct Treatment for Rural and Remote Disordered Gamblers N/A
Recruiting NCT05686772 - Prospective Multicenter Cohort Study Evaluating the Incidence and Risk Factors for Problem Gambling Among Young Adults With First-episode Psychosis
Recruiting NCT03336879 - Repetitive Transcranial Magnetic Stimulation in Gambling Disorder N/A
Recruiting NCT05413564 - Impact of a Self-Exclusion Procedure Optimized by an Extension of the Suspension of Commercial Solicitations N/A
Recruiting NCT05833503 - Integrative Couple Treatment for Gambling/Substance Use Disorder N/A
Completed NCT03477799 - The Effect of Transcranial Direct Current Stimulation on Decision Making and Cognitive Flexibility in Gambling Disorder Phase 3
Active, not recruiting NCT03497247 - Mindfulness-Based Cognitive-Behavioral Therapy for Gambling Disorder N/A
Recruiting NCT04646421 - Responsible Gambling Telephone Intervention to High-risk Gamblers by a State-owned Gambling Operator in Sweden.
Completed NCT03354702 - Physical Activity Pathological Gamblers N/A
Completed NCT03287583 - SBIRT Intervention for Gambling Behaviors N/A
Not yet recruiting NCT04158037 - Don't Go There: A Geospatial mHealth App for Gambling Disorder N/A
Not yet recruiting NCT06467422 - Effects of Transcranial Temporal Interference Stimulation on Risky Decision-making and Impulse Control in Gambling Disorder N/A
Not yet recruiting NCT04738773 - RCT for Gambling and Naltrexone, Using Use Eye-tracking Analysis to Predict Treatment Response Phase 2
Not yet recruiting NCT03493399 - Testing Interference-based Methods to Mitigate Gambling Craving - A Multiple Single Case Design N/A